T-type calcium channel blockade as a therapeutic strategy against renal injury in rats with subtotal nephrectomy

Kidney International

Volumn 73, Issue 7, 2008, Pages 826-834

  Sugano, N ^a,b   Wakino, S ^a   Kanda, T ^a   Tatematsu, S ^a   Homma, K ^a   Yoshioka, K ^a   Hasegawa, K ^a   Hara, Y ^a,b   Suetsugu, Y ^b   Yoshizawa, T ^b   Utsunomiya, Y ^b   Tokudome, G ^b   Hosoya, T ^b   Saruta, T ^a   Hayashi, K ^a  

^a KEIO UNIVERSITY   (Japan)

^b JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Chronic kidney disease; Hypertension; Proteinuria; R( ) efonidipine; Renal fibrosis; Rho Rho kinase; T type Ca2+ channels

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; ANGIOTENSIN II; BETA ACTIN; CALCIUM CHANNEL BLOCKING AGENT; CALCIUM CHANNEL T TYPE; CALCIUM CHANNEL T TYPE ALPHA1G; EFONIDIPINE; RHO KINASE; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; VIMENTIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; ENANTIOMER; ENZYME INDUCTION; KIDNEY BLOOD FLOW; KIDNEY EPITHELIUM; KIDNEY FIBROSIS; KIDNEY INJURY; KIDNEY INTERSTITIUM; KIDNEY PROXIMAL TUBULE; MALE; MESANGIUM CELL; NEPHRECTOMY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEINURIA; RAT; RENAL PROTECTION; SPONTANEOUSLY HYPERTENSIVE HEART FAILURE RAT; STEREOCHEMISTRY; SYSTOLIC BLOOD PRESSURE; TUBULOINTERSTITIAL FIBROSIS;

EID: 40849085208     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/sj.ki.5002793     Document Type: Article

References (42)

1. 2+ channels. Annu Rev Cell Dev Biol 2000; 16: 521-555.
2. Hayashi K, Ozawa Y, Fujiwara K et al. Role of actions of calcium antagonists on efferent arterioles - with special references to glomerular hypertension. Am J Nephrol 2003; 23: 229-244.
3. Loutzenhiser R, Hayashi K, Epstein M. Divergent effects of KCl-induced depolarization on afferent and efferent arterioles. Am J Physiol 1989; 257: F561-F564.
4. Honda M, Hayashi K, Matsuda H et al. Divergent renal vasodilator action of L- and T-type calcium antagonists in vivo. J Hypertens 2001; 19: 2031-2037.
5. Hansen PB, Jensen BL, Andreasen D et al. Differential expression of T- and L-type voltage-dependent calcium channels in renal resistance vessels. Circ Res 2001; 89: 630-638.
6. 2+ channel activation. Am J Nephrol 2004; 24: 641-648.
7. 2+ channel subtypes and pharmacology in the kidney. Circ Res 2007; 100: 342-353.
8. Ozawa Y, Hayashi K, Nagahama T et al. Effect of T-type selective calcium antagonist on renal microcirculation. Hypertension 2001; 38: 343-347.
9. Masuda Y, Tanaka S. Efonidipine hydrochloride: a new calcium antagonist. Cardiovasc Drug Rev 1994; 12: 123-135.
10. Fujiwara K, Kanno Y, Hayashi K et al. Renal protective effects of efonidipine in partially nephrectomized spontaneously hypertensive rats. Clin Exp Hypertens 1998; 20: 295-312.
11. Kanda T, Wakino S, Hayashi K et al. Effect of fasudil on Rho-kinase and nephropathy in subtotally nephrectomized spontaneously hypertensive rats. Kidney Int 2003; 64: 2009-2019.
12. Nishikimi T, Akimoto K, Wang X et al. Fasudil, a Rho-kinase inhibitor, attenuates glomerulosclerosis in Dahl salt-sensitive rats. J Hypertens 2004; 22: 1787-1796.
13. Sun GP, Kohno M, Guo P et al. Involvements of Rho-kinase and TGF-β pathways in aldosterone-induced renal injury. J Am Soc Nephrol 2006; 17: 2193-2201.
14. Narumiya S. The small GTPase Rho: cellular functions and signal transduction. J Biochem 1996; 120: 215-228.
15. Amano M, Chihara K, Kimura K et al. Formation of actin stress fibers and focal adhesions enhanced by Rho-kinase. Science 1997; 275: 1308-1311.
16. Seasholtz TM, Majumdar M, Kaplan DD et al. Rho and Rho kinase mediate thrombin-stimulated vascular smooth muscle cell DNA synthesis and migration. Circ Res 1999; 84: 1186-1193.
17. Nakamura A, Hayashi K, Ozawa Y et al. Vessel- and vasoconstrictor-dependent role of Rho/Rho-kinase in renal microvascular tone. J Vasc Res 2003; 40: 244-251.
18. 2+-dependent activation of Rho and Rho kinase in membrane depolarization-induced and receptor stimulation-induced vascular smooth muscle contraction. Circ Res 2003; 93: 548-556.
19. 2+]i. Am J Physiol Lung Cell Mol Physiol 2005; 289: L574-L582.
20. Hayashi M, Yamaji Y, Nakazato Y et al. The effects of calcium channel blockers on nuclear factor kappa B activation in the mesangium cells. Hypertens Res 2000; 23: 521-525.
21. Ruperez M, Sanchez-Lopez E, Blanco-Colio LM et al. The Rho-kinase pathway regulates angiotensin II-induced renal damage. Kidney Int 2005; 68(Suppl 99): S39-S45.
22. Tanaka H, Komikado C, Shimada H et al. The R(-)-enantiomer of efonidipine blocks T-type but not L-type calcium current in guinea pig ventricular myocardium. J Pharmacol Sci 2004; 96: 499-501.
23. 2+ channels. Br J Pharmacol 2004; 143: 1050-1057.
24. Kimura K, Tojo A, Nanba S et al. Morphometric analysis of arteriolar diameters in experimental nephropathies: application of microvascular casts. Virchows Arch A Pathol Anat Histopathol 1990; 417: 319-323.
25. Sanchez-Lozada LG, Tapia E, Johnson RJ et al. Glomerular hemodynamic changes associated with arteriolar lesions and tubulointerstitial inflammation. Kidney Int 2003; 64(Suppl 86): S9-S14.
26. Mackie FE, Meyer TW, Campbell DJ. Effects of antihypertensive therapy on intrarenal angiotensin and bradykinin levels in experimental renal insufficiency. Kidney Int 2002; 61: 555-563.
27. Bottinger EP. TGF-β in renal injury and disease. Semin Nephrol 2007; 27: 309-320.
28. Baylis C, Qiu C, Engels K. Comparison of L-type and mixed L- and T-type calcium channel blockers on kidney injury caused by deoxycorticosterone-salt hypertension in rats. Am J Kidney Dis 2001; 38: 1292-1297.
29. Cribbs LL, Martin BL, Schroder EA et al. Identification of the T-type calcium channel (Ca(v)3.1d) in developing mouse heart. Circ Res 2001; 88: 403-407.
30. 2+ current is expressed in hypertrophied adult feline left ventricular myocytes. Circ Res 1993; 73: 777-782.
31. Izumi T, Kihara Y, Sarai N et al. Reinduction of T-type calcium channels by endothelin-1 in failing hearts in vivo and in adult rat ventricular myocytes in vitro. Circulation 2003; 108: 2530-2535.
32. Ferron L, Capuano V, Ruchon Y et al. Angiotensin II signaling pathways mediate expression of cardiac T-type calcium channels. Circ Res 2003; 93: 1241-1248.
33. Kaynar K, Ulusoy S, Ovali E et al. TGF-β and TNF-α producing effects of losartan and amlodipine on human mononuclear cell culture. Nephrology 2005; 10: 478-482.
34. Moriyama T, Nagatoya K. The Rho-ROCK system as a new therapeutic target for preventing interstitial fibrosis. Drug News Perspect 2004; 17: 29-34.
35. Ozawa Y, Kobori H. Cruicial role of Rho-nuclear factor-κB axis in angiotensin II-induced renal injury. Am J Physiol 2007; 293: F100-F109.
36. Tian YC, Fraser D, Attisano L et al. TGF-β-mediated alterations of renal proximal tubular cell phenotype. Am J Physiol 2003; 285: F130-F142.
37. Bariety J, Hill GS, Mandet C et al. Glomerular epithelial-mesenchymal transdifferentiation in pauci-immune crescentic glomerulonephritis. Nephrol Dial Transplant 2003; 18: 1777-1784.
38. Rastaldi MP, Ferrario F, Giardino L et al. Epithelial-mesenchymal transition of tubular epithelial cells in human renal biopsies. Kidney Int 2002; 62: 137-146.
39. Manotham K, Tanaka T, Matsumoto M et al. Transdifferentiation of cultured tubular cells induced by hypoxia. Kidney Int 2004; 65: 871-880.
40. Patel S, Takagi K, Suzuki J et al. RhoGTPase activation is a key step in renal epithelial mesenchymal transdifferentiation. J Am Soc Nephrol 2005; 16: 1977-1984.
41. Rodman DM, Reese K, Harral J et al. Low-voltage-activated (T-type) calcium channels control proliferation of human pulmonary artery myocytes. Circ Res 2005; 96: 864-872.
42. Wakino S, Kintscher U, Liu Z et al. Peroxisome proliferator-activated receptor gamma ligands inhibit mitogenic induction of p21 (Cip1) by modulating the protein kinase C delta pathway in vascular smooth muscle cells. J Biol Chem 2001; 276: 47650-47657.